Ray Y Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/643056/publications.pdf

Version: 2024-02-01

		136740	161609
55	3,575	32	54
papers	citations	h-index	g-index
59	59	59	4307
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis. New England Journal of Medicine, 2012, 367, 1508-1518.	13.9	496
2	Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nature Medicine, 2016, 22, 1094-1100.	15.2	247
3	Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infectious Diseases, The, 2011, 11, 516-524.	4.6	234
4	Five-Year Outcomes of the China National Free Antiretroviral Treatment Program. Annals of Internal Medicine, 2009, 151, 241.	2.0	221
5	Distribution of Health Care Expenditures for HIV-Infected Patients. Clinical Infectious Diseases, 2006, 42, 1003-1010.	2.9	148
6	Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis. New England Journal of Medicine, 2017, 377, 1043-1054.	13.9	129
7	Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003–11): a national observational cohort study. Lancet, The, 2013, 382, 1195-1203.	6.3	127
8	PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Science Translational Medicine, 2014, 6, 265ra166.	5.8	126
9	PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Science Translational Medicine, 2014, 6, 265ra167.	5.8	116
10	Risk Factors for Human Illness with Avian Influenza A (H5N1) Virus Infection in China. Journal of Infectious Diseases, 2009, 199, 1726-1734.	1.9	110
11	Prevalence and predictors of HIV infection among female sex workers in Kaiyuan City, Yunnan Province, China. International Journal of Infectious Diseases, 2009, 13, 162-169.	1.5	110
12	Trends in AIDS-Defining and Non-AIDS-Defining Malignancies among HIV-Infected Patients: 1989-2002. Clinical Infectious Diseases, 2004, 39, 1380-1384.	2.9	109
13	Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis. EBioMedicine, 2015, 2, 1627-1633.	2.7	93
14	The Effect of Highly Active Antiretroviral Therapy on Mortality among HIVâ€Infected Former Plasma Donors in China. Clinical Infectious Diseases, 2008, 47, 825-833.	2.9	91
15	Duration of Highly Active Antiretroviral Therapy Regimens. Clinical Infectious Diseases, 2003, 37, 714-722.	2.9	88
16	Cohort Profile: The Chinese national free antiretroviral treatment cohort. International Journal of Epidemiology, 2010, 39, 973-979.	0.9	67
17	Efficacy and Safety of Metronidazole for Pulmonary Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 3903-3909.	1.4	67
18	HIV-Infected Former Plasma Donors in Rural Central China: From Infection to Survival Outcomes, 1985–2008. PLoS ONE, 2010, 5, e13737.	1.1	65

#	Article	IF	Citations
19	A Sterilizing Tuberculosis Treatment Regimen Is Associated with Faster Clearance of Bacteria in Cavitary Lesions in Marmosets. Antimicrobial Agents and Chemotherapy, 2015, 59, 4181-4189.	1.4	59
20	Effect of Diagnostic and Treatment Delay on the Risk of Tuberculosis Transmission in Shenzhen, China: An Observational Cohort Study, 1993–2010. PLoS ONE, 2013, 8, e67516.	1.1	55
21	HIV Prevalence and Risk Behaviors Among Male Clients of Female Sex Workers in Yunnan, China. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 131-135.	0.9	52
22	Impact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China. Aids, 2013, 27, 1815-1824.	1.0	51
23	Predictors of pulmonary tuberculosis treatment outcomes in South Korea: a prospective cohort study, 2005-2012. BMC Infectious Diseases, 2014, 14, 360.	1.3	48
24	Current and future treatments for tuberculosis. BMJ, The, 2020, 368, m216.	3.0	43
25	Mobility, risk behavior and HIV/STI rates among female sex workers in Kaiyuan City, Yunnan Province, China. BMC Infectious Diseases, 2010, 10, 198.	1.3	38
26	HIV Drug Resistance and Its Impact on Antiretroviral Therapy in Chinese HIV-Infected Patients. PLoS ONE, 2013, 8, e54917.	1.1	38
27	Enfuvirtide. Expert Opinion on Investigational Drugs, 2002, 11, 1837-1843.	1.9	36
28	Prevalence and predictors of herpes simplex virus type 2 infection among female sex workers in Yunnan Province, China. International Journal of STD and AIDS, 2008, 19, 635-639.	0.5	36
29	Factors Associated with HIV Virologic Failure Among Patients on HAART for One Year at Three Sentinel Surveillance Sites in China. Current HIV Research, 2011, 9, 103-111.	0.2	36
30	Tracking the Evolution of HIV/AIDS in China from 1989–2009 to Inform Future Prevention and Control Efforts. PLoS ONE, 2011, 6, e25671.	1.1	36
31	Changing baseline characteristics among patients in the China National Free Antiretroviral Treatment Program, 2002-09. International Journal of Epidemiology, 2010, 39, ii56-ii64.	0.9	35
32	Expanding Substance Use Treatment Options for HIV Prevention With Buprenorphine–Naloxone. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 554-561.	0.9	33
33	Mortality and Treatment Outcomes of China's National Pediatric Antiretroviral Therapy Program. Clinical Infectious Diseases, 2013, 56, 735-744.	2.9	32
34	Association Between Missed Early Visits and Mortality Among Patients of China National Free Antiretroviral Treatment Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 59-67.	0.9	30
35	Quantitative 18F-FDG PET-CT scan characteristics correlate with tuberculosis treatment response. EJNMMI Research, 2020, 10, 8.	1.1	27
36	Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis. Science Translational Medicine, 2021, 13 , .	5.8	25

#	Article	IF	Citations
37	Severe Paradoxical Reaction During Treatment of Disseminated Tuberculosis in a Patient With Neutralizing Anti-IFNÎ ³ Autoantibodies. Clinical Infectious Diseases, 2016, 62, 770-773.	2.9	22
38	Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial. Gates Open Research, 2017, 1, 9.	2.0	22
39	Immunologic and Virologic Consequences of Temporary Antiretroviral Treatment Interruption in Clinical Practice. AIDS Research and Human Retroviruses, 2002, 18, 909-916.	0.5	21
40	Application of the BED capture enzyme immunoassay for HIV incidence estimation among female sex workers in Kaiyuan City, China, 2006–2007. International Journal of Infectious Diseases, 2010, 14, e608-e612.	1.5	19
41	The Diagnosis and Treatment of HIV-Infected Children in China. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 429-434.	0.9	17
42	Biomarkers to Monitor Safety in People on ART and Risk of Mortality. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 51-58.	0.9	16
43	A semi-automatic technique to quantify complex tuberculous lung lesions on 18F-fluorodeoxyglucose positron emission tomography/computerised tomography images. EJNMMI Research, 2018, 8, 55.	1.1	16
44	Radiological and functional evidence of the bronchial spread of tuberculosis: an observational analysis. Lancet Microbe, The, 2021, 2, e518-e526.	3.4	16
45	Complete Blood Cell Count as a Surrogate CD4 Cell Marker for HIV Monitoring in Resource-Limited Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 525-530.	0.9	14
46	Sustained HIV Viral Suppression following Treatment Interruption: An Observational Study. AIDS Research and Human Retroviruses, 2006, 22, 40-44.	0.5	12
47	Seroprevalence of Antibodies to Highly Pathogenic Avian Influenza A (H5N1) Virus among Close Contacts Exposed to H5N1 Cases, China, 2005–2008. PLoS ONE, 2013, 8, e71765.	1.1	12
48	A public health approach to rapid scale-up of free antiretroviral treatment in China: an ounce of prevention is worth a pound of cure. Chinese Medical Journal, 2009, 122, 1352-5.	0.9	8
49	Recent key advances in human immunodeficiency virus medicine and implications for China. AIDS Research and Therapy, 2010, 7, 12.	0.7	4
50	Renal Fanconi syndrome with meropenem/amoxicillin-clavulanate during treatment of extensively drug-resistant tuberculosis. European Respiratory Journal, 2017, 50, 1702023.	3.1	4
51	Neurotuberculosis: Control of Steroid-Refractory Paradoxical Inflammatory Reaction With Ruxolitinib. Open Forum Infectious Diseases, 2019, 6, ofz422.	0.4	4
52	Factors associated with survival among adults with HIV-associated TB in Guangxi, China: a retrospective cohort study. Future Virology, 2012, 7, 933-942.	0.9	3
53	Reply to Tham et al. Clinical Infectious Diseases, 2016, 63, 573-574.	2.9	0
54	Country review: China. , 2008, , 253-274.		0

#	Article	IF	CITATIONS
55	Predicting TB treatment outcomes using baseline risk and treatment response markers: developing the PredictTB early treatment completion criteria. Gates Open Research, 0, 4, 157.	2.0	O